ARCHIVES

Erbitux Plus Chemo Effective For NSCLC; Carboplatin Prevents Testicular Recurrence

This article is from The Cancer Letter archive.

Vol. 31 No. 7 | July 25, 2008

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

February 22, 2013

FDA: If Carboplatin Dose Is Based On Actual GFR Measurements, Package Insert Dosing Instructions Accurate

October 8, 2010

ONS Adopts Scope Of Oncology Nursing Practice

November 23, 1984

FDA Offers Grants For Conferences

May 1, 1987

Five Center Core Grants Renewed

February 2, 1979

In Brief: Kirsten To Join NCI As Head of FCRF, AIDS Vaccine Development Thaddeus Domanski Dies

February 5, 1988